Alsmman Alahmady H, Radwan Gamal, Elagouz Mohammed, Mohammed Usama Ali
The Department of Ophthalmology, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt.
Clin Ophthalmol. 2017 Mar 20;11:541-548. doi: 10.2147/OPTH.S128956. eCollection 2017.
To evaluate the efficacy and safety of Alahmady ring implantation in the management of neovascular glaucoma.
A total of 15 eyes of 15 patients with intractable neovascular glaucoma with intraocular pressure (IOP) ≥28 mmHg not responding to medical treatment were retrospectively analyzed. All patients had poor visual acuity and underwent Alahmady ring implantation. The ring was designed from fenestrated silicon tube used in lacrimal surgeries and was implanted subsclerally after passing it through the anterior chamber. Patients were followed up for at least 24 months. Success in this study was defined based on IOP ≥8 mmHg and <21 mmHg, with not more than 1 glaucoma drug, and improvement of patient symptoms and signs with maximum use of beta blocker as antiglaucoma drug.
A total of 15 eyes of 15 patients (9 males [60%] and 6 females [40%]) were analyzed in this study. The mean IOP before surgery was 38.6 mmHg (standard deviation [SD]: 6.98) and it was 14.05 mmHg (SD =7.57) after surgery. The follow-up range was 24-36 months. Success of silicon drainage device was defined as an IOP <21 mmHg on the last follow-up visit. Medications included only beta-blockers and topical steroids for those who were without severe complications or for those who were not in a condition to undergo a further glaucoma surgery.
Alahmady ring implantation proves to be a good surgical option for neovascular glaucoma; however, a longer follow-up period is recommended.
评估阿拉姆迪环植入术治疗新生血管性青光眼的有效性和安全性。
回顾性分析15例难治性新生血管性青光眼患者的15只眼，这些患者眼压（IOP）≥28 mmHg，药物治疗无效。所有患者视力均较差，均接受了阿拉姆迪环植入术。该环由泪道手术中使用的带孔硅胶管制成，经前房穿过巩膜下植入。对患者进行至少24个月的随访。本研究中的成功定义为眼压≥8 mmHg且<21 mmHg，使用不超过1种青光眼药物，最大程度使用β受体阻滞剂作为抗青光眼药物时患者症状和体征有所改善。
本研究共分析了15例患者的15只眼（9例男性[60%]和6例女性[40%]）。术前平均眼压为38.6 mmHg（标准差[SD]：6.98），术后为14.05 mmHg（SD = 7.57）。随访时间为24至36个月。硅胶引流装置的成功定义为最后一次随访时眼压<21 mmHg。对于无严重并发症或不适合进一步进行青光眼手术的患者，药物仅包括β受体阻滞剂和局部类固醇。
阿拉姆迪环植入术被证明是治疗新生血管性青光眼的一种良好手术选择；然而，建议进行更长时间的随访。
